| 2,471 | 5 | 432 |
| 下载次数 | 被引频次 | 阅读次数 |
新冠疫情使得RNA疫苗得到了迅速的发展。本文依据RNA分子形式的不同将RNA疫苗分为三种类型：非复制型传统mRNA疫苗、环状RNA疫苗和自复制型RNA疫苗，并对其技术特点及在新冠病毒领域的研究进展进行综述。
Abstract：The COVID-19 pandemic has promoted rapid advancement of RNA vaccines. This paper reviews the technical characteristics and recent research progress of three types of RNA vaccines, which are classified based on the different forms of RNA molecules: non-replicating traditional mRNA vaccines, circular RNA vaccines and self-replicating RNA vaccines.
[1] Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine,BBIBP-CorV:a randomised, double-blind, placebocontrolled, phase 1/2 trial[J]. Lancet Infect Dis, 2021,21(1):39-51. DOI:10.1016/S1473-3099(20)30831-8.
[2] Wang Y, Yang C, Song Y, et al. Scalable liveattenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy[J]. Proc Natl Acad Sci U S A, 2021, 118(29):e2102775118. DOI:10.1073/pnas.2102775118.
[3] Zhu FC, Li YH, Guan XH, et al. Safety, tolerability,and immunogenicity of a recombinant adenovirus type-5vectored COVID-19 vaccine:a dose-escalation, openlabel, non-randomised, first-in-human trial[J]. Lancet,2020, 395(10240):1845-1854. DOI:10.1016/S0140-6736(20)31208-3.
[4] Loes AN, Gentles LE, Greaney AJ, et al. Attenuated influenza virions expressing the SARS-CoV-2 receptorbinding domain induce neutralizing antibodies in mice[J]. bioRxiv[Preprint], 2020, 12(9):987. DOI:10.1101/2020.08.12.248823.
[5] Yang J, Wang W, Chen Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity[J]. Nature, 2020, 586(7830):572-577. DOI:10.1038/s41586-020-2599-8.
[6] Kauffman KJ, Webber MJ, Anderson DG. Materials for non-viral intracellular delivery of messenger RNA therapeutics[J].J Control Release, 2016, 240:227-234.DOI:10.1016/j.jconrel.2015.12.032.
[7] KarikóK, Muramatsu H, Welsh FA, et al.Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability[J]. Mol Ther, 2008, 16(11):1833-1840. DOI:10.1038/mt.2008.200.
[8] Stepinski J, Waddell C, Stolarski R, et al. Synthesis and properties of mRNAs containing the novel “antireverse” cap analogs 7-methyl(3′-O-methyl)GpppG and 7-methyl(3′-deoxy)GpppG[J]. RNA, 2001, 7(10):1486-1495.
[9] Vaidyanathan S, Azizian KT, Haque AKMA, et al.Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification[J]. Mol Ther Nucleic Acids, 2018, 12:530-542. DOI:10.1016/j.omtn.2018.06.010.
[10]Orlandini von Niessen AG, Poleganov MA, Rechner C, et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3′UTRs identified by cellular library screening[J]. Mol Ther, 2019, 27(4):824-836. DOI:10.1016/j.ymthe.2018.12.011.
[11]Fang E, Liu X, Li M, et al. Advances in COVID-19mRNA vaccine development[J]. Signal Transduct Target Ther, 2022, 7(1):94. DOI:10.1038/s41392-022-00950-y.
[12]Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy[J]. Mol Cancer, 2021, 20(1):41.DOI:10.1186/s12943-021-01335-5.
[13]Xia X. Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines[J].Vaccines, 2021, 9(7):734. DOI:10.3390/vaccines9070734.
[14]Huang L, Zhang H, Deng D, et al. LinearFold:lineartime approximate RNA folding by 5’-to-3’dynamic programming and beam search[J]. Bioinformatics,2019, 35(14):i295-i304. DOI:10.1093/bioinformatics/btz375.
[15]Giessel A, Dousis A, Ravichandran K, et al.Therapeutic enzyme engineering using a generative neural network[J]. Sci Rep, 2022, 12(1):1-17. DOI:10.1038/s41598-022-05195-x.
[16]Zhang H, Zhang L, Lin A, et al. Algorithm for Optimized mRNA Design Improves Stability and Immunogenicity[J]. Nature, 2023,621(7978):396-403.DOI:10.1038/s41586-023-06127-z.
[17]Leppek K, Byeon GW, Kladwang W, et al.Combinatorial optimization of mRNA structure,stability, and translation for RNA-based therapeutics[J].Nat Commun, 2022, 13(1):1-22. DOI:10.1038/s41467-022-28776-w.
[18]Wang Z, Kiledjian M. The poly(A)-binding protein and an mRNA stability protein jointly regulate an endoribonuclease activity[J]. Mol Cell Biol, 2000, 20(17):6334-6341. DOI:10.1128/MCB. 20.17.6334-6341.2000.
[19]Kon E, Elia U, Peer D. Principles for designing an optimal mRNA lipid nanoparticle vaccine[J]. Curr Opin Biotechnol, 2022, 73:329-336. DOI:10.1016/j.copbio.2021.09.016.
[20]Jia L, Qian SB. Therapeutic mRNA Engineering from Head to Tail[J]. Acc Chem Res, 2021, 54(23):4272-4282. DOI:10.1021/acs.accounts.1c00541.
[21]Trepotec Z, Geiger J, Plank C, et al. Segmented poly(A)tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life[J]. RNA, 2019, 25(4):507-518. DOI:10.1261/rna.069286.118.
[22]Durbin AF, Wang C, Marcotrigiano J, et al. RNAs containing modified nucleotides fail to trigger RIG-I conformational changes for innate immune signaling[J].mBio, 2016, 7(5):e00833-16. DOI:10.1128/mBio.00833-16.
[23]Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs[J]. Nat Biotechnol, 2014, 32(5):453-461. DOI:10.1038/nbt.2890.
[24]Salzman J, Gawad C, Wang PL, et al. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types[J]. PLoS One, 2012,7(2):e30733. DOI:10.1371/journal.pone.0030733.
[25]Wesselhoeft RA, Kowalski PS, Anderson DG.Engineering circular RNA for potent and stable translation in eukaryotic cells[J]. Nat Commun, 2018, 9(1):2629. DOI:10.1038/s41467-018-05096-6.
[26]Qu L, Yi Z, Shen Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants[J]. Cell,2022, 185(10):1728-1744. e16. DOI:10.1016/j.cell.2022.03.044.
[27]Sokolova NI, Ashirbekova DT, Dolinnaya NG, et al.Chemical reactions within DNA duplexes. Cyanogen bromide as an effective oligodeoxyribonucleotide coupling agent[J]. FEBS Lett, 1988, 232(1):153-155. DOI:10.1016/0014-5793(88)80406-x.
[28]Moore MJ. Joining RNA molecules with T4 DNA ligase[J]. Methods Mol Biol, 1999, 118:11-19. DOI:10.1385/1-59259-676-2:11.
[29]Puttaraju M, Been MD. Group I permuted intron-exon(PIE)sequences self-splice to produce circular exons[J]. Nucleic Acids Res, 1992, 20(20):5357-5364.DOI:10.1093/nar/20.20.5357.
[30]Dolinnaya NG, Sokolova NI, Ashirbekova DT, et al.The use of BrCN for assembling modified DNA duplexes and DNA-RNA hybrids; comparison with water-soluble carbodiimide[J]. Nucleic Acids Res,1991, 19(11):3067-3072. DOI:10.1093/nar/19.11.3067.
[31]Rausch JW, Heinz WF, Payea MJ, et al. Characterizing and circumventing sequence restrictions for synthesis of circular RNA in vitro[J]. Nucleic Acids Res, 2021, 49(6):e35. DOI:10.1093/nar/gkaa1256.
[32]Meganck RM, Liu J, Hale AE, et al. Engineering highly efficient backsplicing and translation of synthetic circRNAs[J]. Mol Ther Nucleic Acids, 2021, 23:821-834. DOI:10.1016/j.omtn.2021.01.003.
[33]Mikheeva S, Hakim-Zargar M, Carlson D, et al. Use of an engineered ribozyme to produce a circular human exon[J]. Nucleic Acids Res, 1997, 25(24):5085-5094.DOI:10.1093/nar/25.24.5085.
[34]Petkovic S, Müller S. RNA self-processing:formation of cyclic species and concatemers from a small engineered RNA[J]. FEBS Lett, 2013, 587(15):2435-2440. DOI:10.1016/j.febslet.2013.06.013.
[35]Hieronymus R, Müller S. Engineering of hairpin ribozyme variants for RNA recombination and splicing[J]. Ann N Y Acad Sci, 2019, 1447(1):135-143.DOI:10.1111/nyas.14052.
[36]Zonghao Qiu, Qiangbo Hou, Yang Zhao,et al. CleanPIE:a novel strategy for efficiently constructing precise circRNA with thoroughly minimized immunogenicity to direct potent and durable protein expression[J].bioRxiv, 2022:2022.06.20.496777. DOI:10.1101/2022.06.20.496777.
[37]Abu Bakar F, Ng LFP. Nonstructural Proteins of Alphavirus-Potential Targets for Drug Development[J].Viruses, 2018, 10(2):71. DOI:10.3390/v10020071.
[38]Vogel AB, Lambert L, Kinnear E, et al. SelfAmplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses[J]. Mol Ther:The Journal of the American Society of Gene Therapy, 2018, 26(2):446-455. DOI:10.1016/j.ymthe.2017.11.017.
[39]王佳敏，时小双，杜寿文，等. mRNA疫苗——一种新的疫苗策略[J].中国兽医学报，2023,43(05):1099-1106. DOI:10.16303/j.cnki.1005-4545.32023.05.36.
[40]OaConnor MA, Hawman DW, Meade-White K, et al.A replicon RNA vaccine induces durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned[J].
[41]Kr?hling V, Erbar S, Kupke A, et al. Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection[J]. Mol Ther, 2023, 31(2):374-386. DOI:10.1016/j.ymthe.2022.10.011.
[42]Lin G, Yan H, Sun J, et al. Self-replicating RNA nanoparticle vaccine elicits protective immune responses against SARS-CoV-2[J]. Mol Ther Nucleic Acids.2023, 32:650-666.DOI:10.1016/j.omtn.2023.04.021.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.004423
中图分类号:R392
引用信息:
[1]赵小蒙,尹一凡,林敏,等.新冠RNA疫苗研究进展[J].病毒学报,2024,40(01):151-159.DOI:10.13242/j.cnki.bingduxuebao.004423.
基金信息:
福建省基金重点（项目号：2022J02005）,题目：天然感染下非免疫优势表位的功能挖掘及免疫原展示设计~~
2023-07-10
2023
2023-08-21
2024-01-15
2024
1
2023-11-21
2023-11-21
2023-11-21